# COXEN: HCP commentary report

> 406 verified statements (201 from clinicians verified by NPI or staff page) from 62 commentary sources · 10 findings · updated Nov 1, 2026

## Report

- Trial: A Randomized Phase II Study of Co-Expression Extrapolation (COXEN) With Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer
- NCT ID: NCT02177695
- Registry: https://clinicaltrials.gov/study/NCT02177695
- Sponsor: SWOG Cancer Research Network
- Phase: Phase 2
- Status: Completed
- Drugs tested: gemcitabine plus cisplatin; dose-dense MVAC
- Indication: localized muscle-invasive bladder cancer
- Version: v1.0.0, edition 1
- Accepted: 2026-11-01
- Last checked: 2026-11-01
- Release hash: d859d3cb5a3422d2b0c7f7a730e41e92d7ac37c4d610c0b36450c12ca64d07c1

## Counts

- HCP commentary sources screened: 203
- Sources cited by verified statements: 66
- Verified statements: 406
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 201
- Findings: 10
- Named people in screened sources (unnamed speakers and accounts not counted): 62
- Voices cited: 61
- Cited voices identity-verified: 54
- Organisational or shared accounts (not counted as people): 5

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

Clinician commentary on COXEN in the sources reviewed for this edition leads to one open question: What evidence and combined clinical assessment would justify adding, withholding or curtailing treatment without overstating a biomarker's clinical utility? Its leading findings: (1) A response biomarker is not, by itself, permission to omit cystectomy. (2) GC versus ddMVAC remains a conditional choice, not a settled equivalence or universal superiority claim. (3) adding perioperative IO versus reserving risk-adapted adjuvant IO remains a live sequencing dispute. 7 more findings follow. 203 sources screened, 66 cited; not all HCPs or all public discussion.

## Open Medical Affairs question

What evidence and combined clinical assessment would justify adding, withholding or curtailing treatment without overstating a biomarker's clinical utility?

Raised by the leading finding. The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. A response biomarker is not, by itself, permission to omit cystectomy
- F2. GC versus ddMVAC remains a conditional choice, not a settled equivalence or universal superiority claim
- F3. Adding perioperative IO versus reserving risk-adapted adjuvant IO remains a live sequencing dispute
- F4. ctDNA is described as strongly prognostic, but not yet a general rule for starting or stopping IO
- F5. Favorable prognosis after pCR is not the same as trial-level surrogacy for survival benefit
- F6. Failure of the original treatment-specific COXEN objective did not erase the perceived value of S1314
- F7. Multimodal AI attracts strong enthusiasm, with clinical utility and external validation still unresolved
- F8. cfDNA methylation is presented as exploratory proof of concept, not a validated reason to withhold chemotherapy
- F9. Prior BCG and secondary MIBC generate biological questions, not a current mandate to withhold cisplatin-based NAC
- F10. Referral, treatment delivery and local-treatment burden are part of the clinical question

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding.

| Finding | Statements | Passages | Sources | Named voices | Counterview | Limitations |
| --- | ---: | ---: | ---: | ---: | --- | ---: |
| F1 | 39 | 17 | 7 | 8 | recorded | 3 |
| F2 | 54 | 45 | 14 | 23 | recorded | 3 |
| F3 | 48 | 39 | 12 | 15 | recorded | 4 |
| F4 | 17 | 11 | 5 | 6 | none recorded | 3 |
| F5 | 49 | 45 | 8 | 14 | recorded | 3 |
| F6 | 47 | 34 | 18 | 14 | recorded | 3 |
| F7 | 46 | 36 | 15 | 18 | recorded | 4 |
| F8 | 27 | 13 | 5 | 5 | none recorded | 4 |
| F9 | 16 | 16 | 1 | 2 | none recorded | 3 |
| F10 | 19 | 18 | 7 | 9 | recorded | 3 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Passages supporting | Passages giving context | Sources by kind | Feeds the Medical Affairs question |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- | --- |
| F1 | 27 | 2 | 5 | 2 | 3 | 40 | 0 | 5 posts and articles, 2 podcasts and video | yes |
| F2 | 21 | 12 | 5 | 8 | 8 | 58 | 6 | 10 posts and articles, 2 podcasts and video, 2 publications | yes |
| F3 | 23 | 10 | 3 | 5 | 7 | 52 | 4 | 8 posts and articles, 3 podcasts and video, 1 publication | yes |
| F4 | 6 | 2 | 0 | 1 | 8 | 17 | 1 | 2 posts and articles, 2 podcasts and video, 1 publication | yes |
| F5 | 25 | 10 | 2 | 4 | 8 | 53 | 8 | 6 posts and articles, 1 podcast or video, 1 publication | yes |
| F6 | 28 | 4 | 0 | 2 | 13 | 50 | 0 | 13 posts and articles, 3 podcasts and video, 2 publications | yes |
| F7 | 29 | 4 | 3 | 1 | 9 | 48 | 0 | 13 posts and articles, 1 podcast or video, 1 publication | yes |
| F8 | 13 | 2 | 1 | 2 | 9 | 29 | 1 | 3 posts and articles, 2 podcasts and video | yes |
| F9 | 9 | 2 | 3 | 2 | 0 | 16 | 0 | 1 post or article | yes |
| F10 | 10 | 2 | 3 | 2 | 2 | 20 | 3 | 5 posts and articles, 1 podcast or video, 1 publication | yes |

### Trial dimensions

- Primary endpoint: Assessment of Whether the Treatment-specific COXEN Score is Prognostic of pT0 Rate: F6 (7 shared claims)
- Primary endpoint: Assessment of Whether the Treatment-specific COXEN Score is Prognostic of ≤ pT1 Rate: F6 (3 shared claims)
- Primary endpoint: Assessment of COXEN Score as a Predictive Factor Distinguishing Between GC and ddMVAC: F6 (4 shared claims)
- Primary endpoint: Correlation Between GC-and ddMVAC-COXEN Score: no finding draws on it directly
- Secondary endpoint: Predictability of the CO-eXpression ExtrapolatioN (COXEN) Score to Direct Which of the Two Regimens the Patient Should Receive: Gemcitabine+Cisplatin (GC) Versus Dose-dense Methotrexate, Vinblastin, Doxorubicin, and Cisplatin (DDMVAC): F6 (6 shared claims)
- Secondary endpoint: Value of Gene Expression Profiling in Predicting Overall Survival (OS): F2 (1 shared claims), F5 (1 shared claims), F6 (5 shared claims)
- Secondary endpoint: Pathologic T0 Rate Evaluation: Gemcitabine+Cisplatin (GC) Versus Dose-dense Methotrexate, Vinblastin, Doxorubicin, and Cisplatin (DDMVAC): F2 (6 shared claims), F3 (1 shared claims)
- Secondary endpoint: Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs: no finding draws on it directly
- Population and setting: F2 (5 shared claims), F8 (2 shared claims), F9 (2 shared claims)
- The comparison: F2 (34 shared claims), F5 (1 shared claims), F6 (2 shared claims), F10 (1 shared claims)
- Safety and tolerability: F2 (3 shared claims), F6 (1 shared claims), F10 (1 shared claims)
- Design and conduct: F2 (4 shared claims), F6 (7 shared claims)

## Sample findings

Paraphrased; the full report links each statement to its source.

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 10 | Titles free |
| Detailed analysis | 11 sections | Paid |
| Verified statements with short source quotes and links | 406 | Paid |
| Trial aspects mapped | 21 | Free |
| Sources with links | 66 | Counts free |
| Speaker attribution for cited voices | 61 | Paid |

## Trial aspects

19 discussed · 2 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Assessment of Whether the Treatment-specific COXEN Score is Prognostic of pT0 Rate | discussed | 7 | 3 |
| Primary endpoint: Assessment of Whether the Treatment-specific COXEN Score is Prognostic of ≤ pT1 Rate | discussed | 3 | 3 |
| Primary endpoint: Assessment of COXEN Score as a Predictive Factor Distinguishing Between GC and ddMVAC | discussed | 4 | 2 |
| Primary endpoint: Correlation Between GC-and ddMVAC-COXEN Score | no commentary found | 0 | 0 |
| Secondary endpoint: Predictability of the CO-eXpression ExtrapolatioN (COXEN) Score to Direct Which of the Two Regimens the Patient Should Receive: Gemcitabine+Cisplatin (GC) Versus Dose-dense Methotrexate, Vinblastin, Doxorubicin, and Cisplatin (DDMVAC) | discussed | 6 | 3 |
| Secondary endpoint: Value of Gene Expression Profiling in Predicting Overall Survival (OS) | discussed | 5 | 3 |
| Secondary endpoint: Pathologic T0 Rate Evaluation: Gemcitabine+Cisplatin (GC) Versus Dose-dense Methotrexate, Vinblastin, Doxorubicin, and Cisplatin (DDMVAC) | discussed | 7 | 5 |
| Secondary endpoint: Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs | no commentary found | 0 | 0 |
| Population and setting | discussed | 9 | 5 |
| The comparison | discussed | 34 | 11 |
| Safety and tolerability | discussed | 4 | 4 |
| Design and conduct | discussed | 10 | 8 |
| DDR biomarkers, clinical complete response and bladder preservation | discussed | 44 | 10 |
| Pathological response as prognosis, early-phase endpoint and survival surrogate | discussed | 45 | 6 |
| Multimodal AI response prediction and interpretability | discussed | 34 | 14 |
| Exploratory plasma cfDNA methylation | discussed | 27 | 5 |
| Prior BCG, primary versus secondary MIBC and chemotherapy sensitivity | discussed | 16 | 1 |
| Perioperative IO, pathology-directed adjuvant treatment and evolving alternatives | discussed | 46 | 11 |
| ctDNA residual-risk assessment and decision-guiding limits | discussed | 16 | 4 |
| Referral, treatment uptake and cystectomy versus trimodality pathways | discussed | 18 | 6 |
| Molecular subtyping and the distinction between downstaging prediction and survival relevance | discussed | 3 | 2 |

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

## Sources

| Channel | Screened | Cited |
| --- | ---: | ---: |
| X threads | 191 | 53 |
| YouTube | 8 | 7 |
| Podcasts | 3 | 2 |
| Bluesky threads | 1 | 0 |
| Publications (primary source, cited for context) | not screened | 3 |
| Registry (primary source, cited for context) | not screened | 1 |

- Screened window: 2014-07-22 to 2026-09-18
- Cited window: 2014-08-14 to 2026-06-26
- Retrieved: 2026-10-31

Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: A Randomized Phase II Study of Co-Expression Extrapolation (COXEN) With Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer
- Also known as: SWOG S1314
- Registry: NCT02177695 (https://clinicaltrials.gov/study/NCT02177695)
- Study IDs: S1314 · NCI-2014-00850 (National Cancer Institute) · U10CA180888
- Sponsor: SWOG Cancer Research Network
- Collaborators: National Cancer Institute (NCI)
- Design: Phase 2 · interventional, randomized, parallel, phase2
- Status: Completed
- Enrollment: 237 (actual)
- Start: 2014-08-28 (actual)
- Primary completion: 2020-02 (actual)
- Primary endpoint: Assessment of Whether the Treatment-specific COXEN Score is Prognostic of pT0 Rate (Up to 5 years post registration)
- Primary endpoint: Assessment of Whether the Treatment-specific COXEN Score is Prognostic of ≤ pT1 Rate (up to 5 years post-registration)
- Primary endpoint: Assessment of COXEN Score as a Predictive Factor Distinguishing Between GC and ddMVAC (up to 5 years post-registration)
- Primary endpoint: Correlation Between GC-and ddMVAC-COXEN Score (up to 5 years post-registration)
- Intervention: Gemcitabine (drug)
- Intervention: Cisplatin (drug)
- Intervention: Methotrexate (drug)
- Intervention: Vinblastine (drug)
- Intervention: Doxorubicin (drug)
- Intervention: Filgrastim (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- 1 cited commentary passage leaves a source question open, such as who was speaking. The report attributes no further than the source shows.
- Not yet captured in this edition: a view on survival evidence informing neoadjuvant versus adjuvant immunotherapy alongside chemotherapy and surgery.
- Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- 320 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits apply, so some matching discussion may be missing.
- The sources reviewed for this edition do not represent all HCP discussion or support estimates of professional consensus. Multiple posts, reposts or sources are not necessarily independent assessments.
- Trial-name and identifier-focused discovery may miss discussions using unnamed references or different transcription variants. Some available passages were not fully assessed for clinician views, so absence from an aspect is not proof that the issue was never discussed.
- Some spoken passages cannot be assigned to a named participant. They may belong to a named participant in the same program and must not be counted as additional voices.
- A relay preserves another party's statement; it does not establish that the relayer independently endorses the interpretation. Research involvement, professional identity or an organizational account does not increase evidentiary weight.
- The discussions span different evidence maturities, populations and treatment-access circumstances. Approval, reimbursement, investigational status and anticipated readouts are time-specific, not a current comprehensive regulatory assessment.
- S1314 was not designed to settle all secondary regimen or response–survival comparisons, and reduced biomarker evaluability limits precision. Nonsignificance is not equivalence, and prognostic association is not proof of treatment-selection benefit.
- Gene-panel descriptions, unusual regimen wording and methylation performance percentages are not fully consistent across sources. The report preserves those differences rather than selecting an unverified correction.
- Unclear wording about patients not proceeding to surgery does not establish progression, toxicity or another specific clinical reason.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, accepted 2026-11-01: current edition

Last checked for new commentary 2026-11-01. No corrections. Versions follow semver: a new or changed finding is a minor version, more evidence without a material change is a patch.

## Offer

- Size: Deep (406 verified statements)
- Current edition: $1,950. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of weekly updates: $3,400
- 6 months of weekly updates: $4,900
- 12 months of weekly updates: $6,800
- Optional identity linkages (12-month updates only, product updates-12-identities; speakers are named and described in every report): NPI and other verified IDs at $15 per identity-verified person in the edition at purchase (54 now), at most $1,950; people verified later in the term at no charge
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/coxen-nct02177695
- Agents: POST https://www.erudio.com/api/orders with {"report": "coxen-nct02177695", "product": "edition" | "updates-3" | "updates-6" | "updates-12" | "updates-12-identities", "buyer_email": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user (and a pay_url your own MPP or x402 payment client can pay over HTTP 402, when offered), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=coxen-02177695

## Cite

Erudio Health. COXEN (NCT02177695): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 1, 2026. https://www.erudio.com/reports/coxen-nct02177695

## Machine access

- JSON: https://www.erudio.com/reports/coxen-nct02177695.json
- Markdown: https://www.erudio.com/reports/coxen-nct02177695.md
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "coxen-02177695"}`